All In Biotech

Drug Trial Radar · NCT07311564

A Study of LAD603 in Adults With Alopecia Areata

A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

Dec 17, 2025

Primary completion

Jun 23, 2027

Study completion Nov 21, 2027

Sponsor

Lead sponsor
Almirall, S.A.Industry
Sponsor type
Industry
First posted
Dec 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.

Conditions

  • Alopecia Areata

Interventions

  • LAD603Drug

    LAD603 administered subcutaneously.

  • PlaceboOther

    LAD603 matching placebo administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in the Severity of Alopecia Tool (SALT) ScoreTime frame: Baseline, Week 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigator Site 1

    Omaha, Nebraska · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.